Retension Pharmaceuticals Inc. (RTSN) Stock Overview
Explore Retension Pharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.
Retension Pharmaceuticals Inc. (RTSN)
Key Financials
Key Financials
Market Cap
44.7M
P/E Ratio
N/A
EPS (TTM)
$-2.61
ROE
N/A
RTSN Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Retension Pharmaceuticals Inc. (NASDAQ: RTSN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Retension Pharmaceuticals Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of RTSN on the NASDAQ shows an RSI of 100.00, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $N/A for the NASDAQ listing.
Key metrics behind Retension Pharmaceuticals Inc.'s NASDAQ-traded stock include a P/E ratio of N/A and a market capitalization of 44.7M. Combined with our AI analysis, these give both institutional and retail investors a clear view of RTSN on the NASDAQ.